AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 151 min read$ORKA

Goncalves Joana sold $524K of ORKA

Goncalves Joana (Chief Medical Officer) sold 7,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $74.81 ($73.89–$77.71, $0.52M total) across 5 trades on 2026-10-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Goncalves Joana
Published Oct 15, 2026, 10:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 10:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ORKA
Bearish
medium confidence
Mentioned
$ORKA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ORKABearishLow
01

Why it matters

The disclosed sale reduces insider ownership and may be interpreted as a lack of confidence, prompting short‑term price weakness.

02

Market read

Insider sales are closely watched for micro‑caps; this filing provides fresh data for traders.

03

What to watch

Potential upcoming clinical data releases that may offset the sell pressure.

Relevance 4/10Novelty 4/10Timing: after-hours filing

Background

SEC Form 4 filing discloses a 10b5‑1 planned sale by Oruka Therapeutics' CMO.

Company-level read

Ticker impact

$ORKABearishMedium confidence
Context

Chief Medical Officer sold 7,000 shares for $523,647, reducing her stake to 31,771 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A $524K sale by a C-suite insider is material for a micro‑cap biotech and can trigger sell‑side sentiment.

Market effects

Sector

Minimal; typical insider sale for a small biotech with limited sector impact.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be routine liquidity management, not a negative signal.

Key entities

  • company
    Oruka Therapeutics, Inc.

    Biotech firm listed on Nasdaq under ticker ORKA.

  • person
    Goncalves Joana

    Chief Medical Officer of Oruka Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ORKA insider trading history →

Related articles

OCT 27
$ORKAHighAI 8/10

H.C. Wainwright reiterates Oruka Therapeutics stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $120 price target for Oruka Therapeutics (ORKA) after positive Phase 2b trial results for ORKA-001 in psoriasis. The stock rose 14% last week to $90.33, up 226% over a year. Analysts' price targets range from $117 to $200. The trial showed 61% of high-dose patients achieved PASI 100 at Week 16. Phase 3 trials are planned for 2027.

investing.com2 min
OCT 27
$ORKAMedAI 8/10

Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

Oruka Therapeutics reported that its drug ORKA-001 achieved 61% complete skin clearance in a Phase IIb psoriasis study. The company plans to advance the 600-milligram dose into Phase III in early 2027, pending regulatory discussions. Oruka also expects to report week 52 data from the EVERLAST-A study in December, which will test the drug's potential for annual maintenance dosing. The company has over $1 billion in cash, providing runway through a potential biologics license application filing.

finance.yahoo.com2 min